JPMORGAN CHASE & CO - IMMUNOVANT INC ownership

IMMUNOVANT INC's ticker is IMVT and the CUSIP is 45258J102. A total of 114 filers reported holding IMMUNOVANT INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.1%.

Quarter-by-quarter ownership
JPMORGAN CHASE & CO ownership history of IMMUNOVANT INC
ValueSharesWeighting
Q3 2023$16,450,423
+96.0%
428,508
-3.2%
0.00%
+100.0%
Q2 2023$8,394,395
+773.5%
442,509
+613.8%
0.00%
Q1 2023$961,000
+107274.3%
61,992
+23.0%
0.00%
Q4 2022$895
-99.9%
50,414
-69.1%
0.00%
Q3 2022$911,000
-64.2%
163,208
-75.0%
0.00%
Q2 2022$2,548,000
+0.2%
653,181
+41.5%
0.00%
Q1 2022$2,543,000
+97.6%
461,582
+205.6%
0.00%
Q4 2021$1,287,000
-58.7%
151,062
-57.9%
0.00%
Q3 2021$3,118,000
+862.3%
358,793
+1071.1%
0.00%
Q2 2021$324,000
-20.2%
30,637
+21.3%
0.00%
Q1 2021$406,000
-57.9%
25,259
+21.0%
0.00%
Q4 2020$964,000
+53.7%
20,875
+21.2%
0.00%
Q3 2020$627,000
+59.9%
17,219
+7.1%
0.00%
Q2 2020$392,000
+771.1%
16,077
+452.9%
0.00%
Q1 2020$45,0002,9080.00%
Other shareholders
IMMUNOVANT INC shareholders Q3 2022
NameSharesValueWeighting ↓
Alpine Global Management, LLC 4,448,017$17,347,0004.39%
Deep Track Capital, LP 9,455,000$36,875,0002.42%
INTERNATIONAL BIOTECHNOLOGY TRUST PLC 233$60,000,0000.63%
Octagon Capital Advisors LP 579,061$2,258,0000.60%
Eventide Asset Management 5,372,512$20,953,0000.45%
WITTENBERG INVESTMENT MANAGEMENT, INC. 174,000$679,0000.29%
Frazier Life Sciences Management, L.P. 585,759$2,284,0000.22%
BCK CAPITAL MANAGEMENT LP 54,293$212,0000.16%
PLATINUM INVESTMENT MANAGEMENT LTD 777,590$3,033,0000.12%
Bridgefront Capital, LLC 15,649$61,0000.07%
View complete list of IMMUNOVANT INC shareholders